<DOC>
	<DOCNO>NCT02986139</DOCNO>
	<brief_summary>Assess injection site pain associate New Etanercept formulation adult subject RA PsA</brief_summary>
	<brief_title>Assess Injection Site Pain Associated With New Etanercept Formulation Adult Subjects With RA PsA</brief_title>
	<detailed_description>This phase 4 , multicenter , randomize , double-blind , 2-period , 2-sequence crossover study subject RA PsA naive etanercept . The study evaluate injection site pain associate commercial formulation etanercept new formulation etanercept immediately injection formulation.The study consist screen period 14 day , 2 week treatment period 30 day post treatment safety follow . Each dose follow recommend label dose subject RA PsA : 50 mg weekly ( schedule approximately 7 day apart ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion Criteria Subject provide informed consent prior initiation study specific activities/procedures . Male female subject 18 year age old time signing informed consent form . Subject diagnosis RA PsA indicate treatment etanercept per current label , base investigator judgment . Subject naïve etanercept . Subject able selfinject etanercept . Exclusion Criteria Subject diagnose Felty 's syndrome . Subject active erythrodermic , pustular , guttate psoriasis , medication induce psoriasis , skin condition . Subject history clinically significant skin allergy Subject history alcoholic hepatitis , nonalcoholic steatohepatitis immunodeficiency syndrome . Subject active infection antiinfectives indicate within 4 week prior screen . Subject serious infection , define require hospitalization intravenous antiinfectives within 8 week prior first dose investigational product . Subject prosthetic joint infection within 5 year screen native joint infection within 1 year screening . Subject know alcohol addiction dependency . Subject positive hepatitis B surface antigen , hepatitis B core antibody ( confirm HBV DNA test ) hepatitis C virus antibody serology screening , positive medical history hepatitis B C. ( Subjects history hepatitis B vaccination without history hepatitis B allow enroll ) . Subject active malignancy , include evidence cutaneous basal squamous cell carcinoma melanoma . Subject known history active tuberculosis . Subject use biologic disease modify agent ( DMARD ) less equal 3 month prior screen . If subject receive continuous treatment acetaminophen , nonsteroidal antiinflammatory drug tramadol , hydrocodone , oxycodone , codeine , and/or propoxyphene dose within 4 hour study visit dose stable ≥ 2 week first dose investigational product For subject continuous analgesic , subject take follow within 4 hour screen : acetaminophen , nonsteroidal antiinflammatory drug , hydrocodone , codeine , tramadol , propoxyphene , and/or oxycodone ( unless form OxyContin ) . For subject continuous analgesic , subject take OxyContin within 24 hour screen . Subject receive live vaccine less equal 4 week prior first dose investigational product . Subject laboratory abnormality screen . Estimated creatinine clearance le 50 mL/min . Subject laboratory abnormality , , opinion investigator pose safety risk , prevent subject complete study , interfere interpretation study result . Subject currently receive treatment another investigational device drug study , less 30 day since end treatment another investigational device drug study ( ) . Other investigational procedure participate study . Women pregnant breastfeeding , plan become pregnant breastfeed treatment and/or within 4 week last dose etanercept . Women childbearing potential positive pregnancy test . Women childbearing potential unwilling practice true sexual abstinence unwilling use 1 follow effective birth control method treatment additional 4 week last dose etanercept .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>